NFKB1 and breast carcinoma: Taken together, we demonstrated that TAK1 inhibitor NG25 can suppress the Dox-induced NF-κB and MAPK signaling pathway activation, which subsequently sensitized breast cancer cells to Dox-mediated cytotoxic effect and this effect is observed in all major breast cancer cell subtypes.